<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250502065562N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-11-13</date_registration>
      <primary_sponsor>Shahre-kord University of Medical Sciences</primary_sponsor>
      <public_title>Studying the effect of corticosteroids on preterm labor</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of intermittent dose of betamethasone, dexamethasone and daily dose of betamethasone on maternal blood sugar and fetal outcome in mothers exposed to preterm delivery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>165</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/83545</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Following verification of the inclusion and exclusion criteria and obtaining written informed consent, participants’ identifying information, including their names and national identification numbers, will be coded by an independent research assistant who will not be involved in participant recruitment, administration of the therapeutic interventions, or outcome assessment. The link between participants’ identities and their assigned codes will be kept confidential.
Participants will then be stratified according to their gestational age at study entry into two strata: 26–30 weeks and 31–34 weeks of gestation. An independent random allocation sequence will be generated for each stratum using R software. Block randomization with variable block sizes of 3 and 6 will be employed. Block sizes will be randomly selected, such that each block of three contains one allocation to each of the three study groups, while each block of six contains two allocations to each group. The order of allocations within each block will also be determined randomly. Accordingly, participants in each stratum will be allocated to the three study groups in a 1:1:1 ratio.
The random allocation sequences will be held by an independent research assistant who will not be involved in participant recruitment, administration of the therapeutic interventions, or outcome assessment. To ensure allocation concealment, sequentially numbered, opaque, sealed envelopes will be prepared according to the randomization sequences. Following final confirmation of a participant’s eligibility and acquisition of written informed consent, the envelope corresponding to the participant’s gestational age stratum will be opened to reveal the assigned treatment group. The treatment allocation will be disclosed only after the participant’s enrollment in the study has been formally confirmed, Blinding description: Following the acquisition of informed consent—obtained via written forms and the provision of adequate information regarding the study objectives, study groups, and the specific intervention for each—participants are randomly assigned to study groups; however, they remain unaware of their specific group assignment. To ensure concealment, the individual responsible for randomization operates independently of the other researchers, and sealed, opaque envelopes are utilized. Consequently, the outcome assessor, the principal investigator, and the patients remain blind to the assigned group throughout the study (double-blinding).</study_design>
      <phase>1-2</phase>
      <hc_freetext>Maternal blood sugar and fetal outcome including neonatal lung maturity, NICU admission, first-minute Apgar score, and birth weight in infants of mothers receiving corticosteroids with preterm delivery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group 1 (55 pregnant women at risk of preterm labor between 26 and 34 weeks of gestation, presenting to Hajar Hospital) receives Betamethasone acetate (Exir Pharmaceutical Company) in six 4 mg doses administered at 8-hour intervals over a period of two days. Intervention 2: Control group: (55) Pregnant women at risk of preterm labor between 26 and 34 weeks of gestation, presenting to Hajar Hospital, receive Betamethasone acetate (Exir Pharmaceutical Company) in six 4 mg doses administered at 8-hour intervals over a period of two days. Intervention 3: Second intervention group (55 pregnant women at risk of preterm labor between 26 and 34 weeks of gestation, presenting to Hajar Hospital): Participants receive four 6 mg doses of dexamethasone (Raha Pharmaceutical Company) at 12-hour intervals over a period of two days.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Some data such as blood sugar and fetal outcomes including NICU admission and lung maturity are shared.

When:
Access period starts 6 months after results are published.

To whom:
Researchers working in academic and scientific institutions and medical students

Conditions:
The data can be used for scientific research in the pharmaceutical industry and to determine new protocols for administering corticosteroids in preterm labor. The data can also be used by academic researchers.

Where to obtain:
To receive the data, individuals can send their request to Fatemeh Abbasian's Gmail address: abbasian.fa2001@gmail.com.

How to obtain:
The requests will be reviewed by me, Fatemeh Abbasian, and after verification of the applicant's individual or organization's details, the Hajar Clinical Research Center and relevant organizations at Shahrekord University of Medical Sciences will respond within a period of approximately two months.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fatemeh Abbasian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Clinic No. 1, Hajar Hospital, Parastar Street, Shahr-e-kord</address>
        <city>Shar-e-kord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۸۱۶۸۵۴۶۳۳</zip>
        <telephone>+98 38 3110 7000</telephone>
        <email>fa_aba_1119@yahoo.com</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sheida Shabanian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Clinic No. 1, Hajar Hospital, Parastar Street, Shahrekord</address>
        <city>Shahrekord</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۸۸۱۶۸۵۴۶۳۳</zip>
        <telephone>+98 38 3225 2416</telephone>
        <email>Shabanian@skums.ac.ir</email>
        <affiliation>Shahre-kord University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Pregnant women at risk of preterm birth who are at 26-34 weeks of gestation.
2. Women who have indications for receiving corticosteroids before pregnancy. (Risk of preterm birth, short cervix, intrauterine growth retardation, twins, decreased fetal movements, antepartum hemorrhage, oligohydramnios, cholestasis, in vitro fertilization, fibroids, poor obstetric history, and Rh isoimmunization are common cases for antepartum steroid therapy.)</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>gestational diabetes or chronic diabetes
use of any medication except for supplements during pregnancy, such as epilepsy or blood pressure medications.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>060</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Onset (spontaneous) of labour before 37 completed weeks of gestation</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1 (55 pregnant women at risk of preterm labor between 26 and 34 weeks of gestation, presenting to Hajar Hospital) receives Betamethasone acetate (Exir Pharmaceutical Company) in six 4 mg doses administered at 8-hour intervals over a period of two days.</i_keyword>
      <i_keyword>Control group: (55) Pregnant women at risk of preterm labor between 26 and 34 weeks of gestation, presenting to Hajar Hospital, receive Betamethasone acetate (Exir Pharmaceutical Company) in six 4 mg doses administered at 8-hour intervals over a period of two days.</i_keyword>
      <i_keyword>Second intervention group (55 pregnant women at risk of preterm labor between 26 and 34 weeks of gestation, presenting to Hajar Hospital): Participants receive four 6 mg doses of dexamethasone (Raha Pharmaceutical Company) at 12-hour intervals over a period of two days.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Maternal blood sugar. Timepoint: The amount of sugar in the blood, which can be measured daily as fasting sugar, immediately after corticosteroid administration for up to 2 days. Method of measurement: Blood test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Infant lung maturity. Timepoint: After the baby is born. Method of measurement: Need for NICU admission due to lung immaturity.</sec_outcome>
      <sec_outcome>Admission to the NICU. Timepoint: After the baby is born. Method of measurement: Need for NICU admission for a reason other than lung immaturity.</sec_outcome>
      <sec_outcome>Apgar after birth. Timepoint: After the baby is born. Method of measurement: File reading.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahre-kord University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-05-18</approval_date>
        <contact_name>Research Ethics Committee of Shahrekord University of Medical Sciences</contact_name>
        <contact_address>Shahrekord, Kashani Blvd., University Headquarters, Building No. 2 Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
